Abstract Title:

[Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo)].

Abstract Source:

Pediatr Med Chir. 1984 Mar-Apr;6(2):241-5. PMID: 6397729

Abstract Author(s):

G Longo, I Rudoi, M Iannuccelli, R Strinati, F Panizon

Abstract:

Thirty patients (mean age: 10.38 years) affected by primary headache were selected for a double-blind cross-over clinical trial. The patients were randomized into 2 homogeneous groups of 15 and treated for 12 weeks with L-5-HTP (100 mg/day) and placebo as per the following design: placebo - L-5-HTP (group A) and L-5-HTP - placebo (group B). Evaluation was carried out every 3 weeks by the Migraine Index supplying a general assessment of the attacks, i.e. severity, duration and frequency. The decrease in mean score values was directly proportional to L-5-HTP treatment, and statistical significance (Wilcoxon's test) was observed only for L-5-HTP in both groups, from 0.05 to 0.01. Improvement, as evaluated by CGI on percentage distribution of the patients, was homogeneous in both groups.

Study Type : Human Study

Print Options


Key Research Topics

Popular Threads

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2016 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.